DICEMBRE 2025
IMMUNOTHERAPY
Prof. Ignacio Melero
Cima Universitad de Navarra, Pamplona, Spain
ESMO Immuno-Oncology 2025 Award keynote lecture: Combining immunotherapies in a quest for synergies
Prof. Marco Donia
University of Copenhagen, Herlev Hospital, Copenhagen, Denmark
Overview sessione “Treatment approaches for checkpoint inhibitor-resistant tumors”
Cellular therapies and T cell engagers
Dott.ssa Margaret Ottaviano
IRCCS Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Italia
Combination of CPI + CPI and other classical agents
Prof.ssa Emanuela Romano
Institut Curie, Paris, France
Overview sessione “Cancer vaccines”
Overview sessione “The future of non- or unconventional T cell targeted immunotherapy”
Prof.ssa Sine Reker Hadrup
DTU Health Tech, Lyngby, Denmark
Using AI to advance therapeutic development of immunotherapies
Prof.ssa Jarushka Naidoo
Beaumont Hospital, RCSI-University of Medicine and Health Sciences, Dublin, Ireland
Monitoring of side effects in patients undergoing immunotherapy
Prof.ssa Alessandra Curioni-Fontecedro
University of Fribourg, Fribourg, Switzerland
New predictive biomarkers for ICB
LUNG-CANCERS
Prof. Andreas Pircher
Medical University, Innsbruck, Austria
Neoadjuvant induction with pembrolizumab (Pembro) plus lenvatinib (Len) in resectable early-stage NSCLC impacts the tumor microenvironment (TME): Clinical results including multi-omic deconvolution of the TME from the INNWOP01 study
SKIN-CANCERS
Dott.ssa Margaret Ottaviano
IRCCS Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Italia
Efficacy and Safety of Neoadjuvant Cemiplimab in Cutaneous Squamous Cell Carcinoma
OTTOBRE 2025
IMMUNOTHERAPY
Prof. Michele Maio
Azienda ospedaliera-universitaria Senese, Siena, Italia
State of the art e prospettive future sull’immunoterapia
LUNG-CANCERS
Prof. Diego Luigi Cortinovis
Fondazione IRCCS San Gerardo dei Tintori, Monza (MB), UniMib, Italia
NSCLC: selezione dei late breaking abstracts
Prof. Marcello Tiseo
Prof. Marcello Tiseo Azienda Ospedaliera-Universitaria Parma, Parma, Italia
Overview sessione “Mini oral session 2: Non-metastatic NSCLC”
Prof. Emilio Bria
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Ospedale Isora Tiberina- Gemelli Isola, Roma, Italia
Final overall survival (OS) and safety analysis of the Phase 3 ALEX study of alectinib vs crizotinib in patients with previously untreated, advanced ALK-positive (ALK+) non-small cell lung cancer (NSCLC)
Association between patient-reported outcomes (PROs) and overall survival (OS) in aNSCLC patients treated with first-line (1L) cemiplimab-based therapy
SKYSCRAPER-03: Phase 3, open-label, randomised study of atezolizumab (atezo) + tiragolumab (tira) vs durvalumab (durva) in locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC) after platinum-based concurrent chemoradiation (cCRT)
OVARIAN-CANCERS
Dott.ssa Valentina Tuninetti
Università degli Studi di Torino, A.O. Ordine Mauriziano, Ospedale Umberto I, Torino, Italia
- Tumore ovarico: best abstracts
- Pembrolizumab vs placebo plus weekly paclitaxel ± bevacizumab in platinum-resistant recurrent ovarian cancer: Results from the randomized double-blind phase III ENGOT-ov65/KEYNOTE-B96 study
- Tumore ovarico: best abstracts
- ROSELLA (GOG3073, ENGOTov72, APGOT-OV10): Relacorilant + nab-paclitaxel in the subgroup of patients with platinum-resistant ovarian cancer (PROC) previously exposed to a PARP inhibitor
SKIN-CANCERS
Prof. Paolo Bossi
IRCCS Humanitas Research Hospital, Rozzano (MI), Italia
Evaluation of the Use of Adjuvant Immunotherapy from a Medical Oncologist's Perspective
Analysis of second primary cutaneous squamous cell carcinoma (CSCC) tumors (SPTs) reported during the C-POST trial, a randomized phase III study of adjuvant cemiplimab vs placebo (pbo) for high-risk CSCC
Dott.ssa Margaret Ottaviano
IRCCS Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Italia
Adjuvant cemiplimab for high-risk cutaneous squamous cell carcinoma: Evaluating dosing intervals in a phase III trial
CemiplimAb-rwlc survivorship and epidemiology (CASE): A prospective, non-interventional study of the safety and effectiveness of cemiplimab in immunocompromised/immunosuppressed (IC/IS) patients with advanced cutaneous squamous cell carcinoma (CSCC) at 2 years’ follow-up
NEO-TIM: Predictive biomarkers and long-term outcomes in the NEO-TIM trial of neoadjuvant immunotherapy and targeted therapy in melanoma
Prof.ssa Anna Di Giacomo
Azienda ospedaliera-universitaria Senese, Siena, Italia
Primary results from a randomized phase II trial of BNT111 in combination with cemiplimab with calibrator monotherapy arms in anti-PD-(L)1 relapsed/refractory melanoma
Final, 9-year results from the CheckMate 238 phase III trial of adjuvant nivolumab vs ipilimumab in resected stage IIIB–C or IV melanoma
Dott. Francesco Spagnolo
IRCCS Ospedale Policlinico San Martino, Genova, Italia
Integrated immune and genomic liquid biopsy profiling in patients with advanced cutaneous squamous cell carcinoma (CSCC) treated with anti-PD-1 therapy
Outcomes from discontinuation of immune checkpoint inhibitors (ICI) following response in patients with advanced cutaneous squamous cell carcinoma (cSCC)
PLUME: A single-arm phase II trial of pembrolizumab (pembro) plus lenvatinib (lenva) in patients (pts) with metastatic uveal melanoma (mUM)
Dott. Jacopo Pigozzo
Istituto Oncologico Veneto IRCCS, Padova, Italia
Two-year clinical update and first biomarker analyses of the phase 3 NADINA trial comparing neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in resectable stage III melanoma
Neoadjuvant plus adjuvant treatment with cemiplimab in surgically resectable, high risk stage III/IV (M0) cutaneous squamous cell carcinoma (NEO-CESQ): Biomarker analysis
Dott. Luca Tagliaferri
Fondazione Policlinico Universitario «Agostino Gemelli», IRCCS, Università Cattolica del Sacro Cuore, Roma, Italia
The Role of Radiotherapy in an Integrated Interdisciplinary Scenario
HR+HER2-
Dott. Armando Orlandi
Policlinico Universitario A. Gemelli IRCCS, Roma, Italia
monarchE: Primary overall survival (OS) results of adjuvant abemaciclib + endocrine therapy (ET) for HR+, HER2-, high-risk early breast cancer (EBC)
Prof. Matteo Lambertini
Università di Genova, Italia
Overview sessione “Cancer and fertility” e approfondimento POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) trial
Overview sessione “The impact of drug adherence on early breast cancer outcomes” e focus sull’aggiornamento del monarchE trial
Prof.ssa Grazia Arpino
Università Federico II, Napoli, Italia
- Imlunestrant plus abemaciclib versus fulvestrant plus abemaciclib in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): An indirect treatment comparison (ITC) of three phase 3 trials
Prof. Paolo Vigneri
Università di Catania, Humanitas Istituto Clinico Catanese, U.O. Oncologia Universitaria, Catania, Italia
5-year follow-up results from the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) trial Da aggiungere ultimo pezzo della registrazione
Impact of estrogen receptor expression on real-world effectiveness of first-line ET+CDK4/6i in patients with HR+/HER2- advanced BC
Prof. Alberto Zambelli
Università degli Studi Milano Bicocca, ASST Papa Giovanni XXIII, Bergamo, Italia
MonarchE: Evaluation of prognostic and predictive value of Ki-67 index pre and post neoadjuvant chemotherapy (NAC) and changes following NAC
PIKALO-1: A phase I/II trial of LY4064809 (STX-478), a pan-mutant-selective PI3Kα inhibitor in PIK3CA-mutant (PIK3CAm) advanced breast cancer (ABC) and other solid tumors
Refining OncotypeDX prognosis and prediction in early breast cancer (eBC): Clinical insights from RSC4All external validation
Prof.ssa Carmen Criscitiello
IRCCS Humanitas Research Hospital, Rozzano (MI), Italia
monarchE: Primary overall survival (OS) results of adjuvant abemaciclib + endocrine therapy (ET) for HR+, HER2-, high-risk early breast cancer (EBC)
Prof.ssa Maria Vittoria Dieci
Università di Padova, Istituto Oncologico Veneto IRCCS, Padova, Italia
Prognostic impact of PIK3CA mutations in patients with endocrine-resistant ER+/HER2- advanced breast cancer: Results from the CHAMBER study
Prof. Andrea Botticelli
Policlinico Umberto I, Università "Sapienza" Roma, Italia
UK real-world risk of recurrence by nodal status in patients with node-positive HR+, HER2- early breast cancer (EBC)
ROME Trial: Predictive value of TMB cutoffs, concordance, and treatment line in immunotherapy for hTMB/MSS cancers
Dott. Michele Bottosso
Università di Padova, Istituto Oncologico Veneto IRCCS, Padova, Italia
Change in breast cancer phenotype after progression to first-line CDK4/6 inhibitors
FEBBRAIO 2025
HOT-TOPICS
Dott.ssa Sarah Scagliarini
Oncologia, AORN Antonio Cardarelli, Napoli, Italia
- Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Final follow-up results from the CheckMate 9ER trial
- Updated results from the phase 2 LITESPARK-003 study of belzutifan plus cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC)
- Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC): Final results of COSMIC-313
Prof.ssa Lorena Incorvaia
Università degli Studi di Palermo, Palermo, Italia
- Cabozantinib (cabo) and nivolumab (nivo) with or without CBM588 in patients with metastatic renal cell carcinoma: Updated clinical outcomes of a phase I study.
- Survival of patients with metastatic renal cell carcinoma with or without brain metastases
Dott.ssa Annalisa Zeppelini
ASST Grande Ospedale Metropolitano Niguarda, Milano, Italia
- Association between site of metastases and survival stratification of the IMDC classification in metastatic renal cell carcinoma (mRCC)
- Renal cell carcinoma in kidney transplant recipients receiving immunosuppression: A 55-year retrospective single-center study
Dott.ssa Stefania Di Girolamo
AUSL Reggio Emilia, Arcispedale Santa Maria Nuova, Reggio Emilia, Italia
- Evaluating the efficacy of cabozantinib in patients with advanced renal cell carcinoma with bone metastasis: An open-label phase 2 study
- The CABOLD study: A real life prospective cohort evaluating the combination of cabozantinib and nivolumab among older patients with renal-cell carcinoma
Dott.ssa Marilena Di Napoli
Istituto Nazionale Tumori, IRCCS Fondazione Pascale, Napoli, Italia
- A phase 2 study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer, (HCRN GU18-343) ABATE study
- Immune and inflammatory profiling in bladder cancer: Insights into biomarkers and therapeutic strategies
- Patient perceptions about their treatment for muscle-invasive bladder cancer (MIBC) over the last decade
Dott. Matteo Perrino
IRCCS Humanitas Research Hospital, Rozzano (MI), Italia
- Real-world epidemiology and clinical outcomes of bladder cancer patients in Spain: BLARWE multicenter study
- Clinical characteristics and treatment patterns of patients with muscle invasive bladder cancer: A real-world cohort study
Dott. Francesco Carrozza
Ospedale Civile Santa Maria delle Croci, AUSL della Romagna, UOC Oncologia, Ravenna, Italia
- A phase 1b study of cabozantinib and nivolumab with abiraterone (CABIOS) in metastatic castration-sensitive prostate cancer (mCSPC): Updated safety, efficacy, and immunologic findings
- Real-world treatment patterns and survival in men with metastatic castration-resistant prostate cancer (mCRPC) who previously progressed from metastatic hormone-sensitive prostate cancer (mHSPC) between 2020 to 2023 in the United States
- The prognostic significance of circulating tumor DNA in prostate cancer: A systematic review and meta-analysis
Dott. Edoardo Lenci
AST Pesaro, Pesaro, Italia
- Characterization of circulating tumor DNA (ctDNA) burden and its association with real-world overall survival among prostate cancer (PC) patients
- Real-world treatment patterns in patients diagnosed with metastatic castration-resistant prostate cancer in the US, 2018-2023
SETTEMBRE 2024
IMMUNOTHERAPY
Prof. Diego Luigi Cortinovis
Fondazione IRCCS San Gerardo dei Tintori, Monza (MB), Italia
- MET×MET bispecific antibody davutamig (REGN5093) for MET-altered advanced non-small cell lung cancer (aNSCLC): Update from a first-in-human (FIH) study
- Tempi più brevi per nuovi farmaci e sperimentazioni cliniche: le richieste degli oncologi dal congresso Esmo
Prof. Emilio Bria
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italia
- Mechanisms of acquired resistance to first-line amivantamab plus lazertinib versus osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer: An early analysis from the phase III MARIPOSA study
- Le combinazioni in immunoterapia
Prof. Marcello Tiseo
Azienda Ospedaliera-Universitaria Parma, Parma, Italia
- A prospective study on clinicians’ attitudes and survival outcomes for patients with NSCLC and poor performance status in the immunotherapy era: PICASO study (GOIRC-04-2020)
- Quali sono le prospettive future dell’immunoterapia?
Dott.ssa Fabiana Vitiello
Azienda Ospedaliera dei Colli, Ospedale Monaldi, Napoli, Italia
- Overview sugli studi sul cemiplimab
Dott. Alessandro Russo
Istituto Clinico Catanese Humanitas, Catania, Italia
- Mechanisms of acquired resistance to first-line amivantamab plus lazertinib versus osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer: An early analysis from the phase III MARIPOSA study
- Real-world second-line outcomes of NSCLC patients receiving first-line chemotherapy plus immunotherapy
Dott.ssa Alessandra Bearz
CRO Aviano, PN, Italia
- Nivolumab (NIVO) plus relatlimab with platinum-doublet chemotherapy (PDCT) vs NIVO + PDCT as first-line (1L) treatment (tx) for stage IV or recurrent NSCLC: Results from the randomized phase II RELATIVITY-104 study
- Real-world second-line outcomes of NSCLC patients receiving first-line chemotherapy plus immunotherapy
Dott. Luca Toschi
IRCCS Humanitas Research Hospital, Rozzano (MI), Italia
- Risk model for overall survival (OS) based on composite patient-reported outcomes (PROs) in NSCLC patients treated with first-line (1L) cemiplimab-based therapy
Prof. Michele Maio
Azienda ospedaliera-universitaria Senese, Siena, Italia
- Nivolumab plus ipilimumab and ASTX727 or nivolumab plus ipilimumab in PD-1 resistant metastatic melanoma: Primary analysis of the randomized phase II NIBIT-ML1 study
- State of the art e prospettive future dell’immunoterapia
Dott.ssa Margaret Ottaviano
IRCCS Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Italia
- Long-term follow-up of advanced melanoma (unresectable/metastatic - aMel) patients (pts) treated with fianlimab (FIAN) + cemiplimab (CEMI): Results from blinded independent central review (BICR) efficacy assessment
- Neoadjuvant cemiplimab for stage II–IV cutaneous squamous cell carcinoma (CSCC): 2-year follow-up and biomarker analyses
Dott.ssa Elisabetta Gambale
Azienda Ospedaliera Universitaria Careggi, Firenze, Firenze, Italia
- Overview sessione “Non-cutaneous melanoma and non-melanoma skin cancers: There is much more we can do”
- Le future prospettive nei tumori cutanei
Prof. Paolo Bossi
IRCCS Humanitas Research Hospital, Rozzano (MI), Italia
- Neoadjuvant cemiplimab with platinum-doublet chemotherapy and cetuximab to de-escalate surgery and omit adjuvant radiation in locoregionally advanced head & neck squamous cell carcinoma (HNSCC)
- Overview generale sessioni Head& Neck
Dott.ssa Vanda Salutari
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italia
- Oncologia ginecologica: take home messages
Dott.ssa Giusy Scandurra
Azienda Ospedaliera Cannizzaro, Catania, Italia
- ESMO 2024 e tumori ginecologici: cosa ci portiamo a casa?
Prof. Mario Mandalà
Università degli Studi di Perugia, Azienda Ospedaliera di Perugia, Italia
- Overview sessione “Improving the management of toxicities from immunotherapy”